Research ArticleBasic Science Investigations
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Melpomeni Fani, Friederike Braun, Beatrice Waser, Karin Beetschen, Renzo Cescato, Judit Erchegyi, Jean E. Rivier, Wolfgang A. Weber, Helmut R. Maecke and Jean Claude Reubi
Journal of Nuclear Medicine September 2012, 53 (9) 1481-1489; DOI: https://doi.org/10.2967/jnumed.112.102764
Melpomeni Fani
1Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
Friederike Braun
1Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
Beatrice Waser
2Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland; and
Karin Beetschen
2Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland; and
Renzo Cescato
2Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland; and
Judit Erchegyi
3Clayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, California
Jean E. Rivier
3Clayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, California
Wolfgang A. Weber
1Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
Helmut R. Maecke
1Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
Jean Claude Reubi
2Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland; and

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 53, Issue 9
September 1, 2012
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Melpomeni Fani, Friederike Braun, Beatrice Waser, Karin Beetschen, Renzo Cescato, Judit Erchegyi, Jean E. Rivier, Wolfgang A. Weber, Helmut R. Maecke, Jean Claude Reubi
Journal of Nuclear Medicine Sep 2012, 53 (9) 1481-1489; DOI: 10.2967/jnumed.112.102764
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Melpomeni Fani, Friederike Braun, Beatrice Waser, Karin Beetschen, Renzo Cescato, Judit Erchegyi, Jean E. Rivier, Wolfgang A. Weber, Helmut R. Maecke, Jean Claude Reubi
Journal of Nuclear Medicine Sep 2012, 53 (9) 1481-1489; DOI: 10.2967/jnumed.112.102764
Jump to section
Related Articles
Cited By...
- Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells
- Optimized Methods for the Production of High-Purity 203Pb Using Electroplated Thallium Targets
- Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study
- 225Ac-MACROPATATE: A Novel {alpha}-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
- A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
- First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
- Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
- Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
- Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists
- Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
- Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
- SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
- Somatostatin Receptor Antagonists for Imaging and Therapy
- Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
- Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms
- Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET
- In Vivo Radioimaging of Bradykinin Receptor B1, a Widely Overexpressed Molecule in Human Cancer
- Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging
- Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study